
Neoadjuvant Nivolumab Plus Chemo Significantly Improves OS Vs Chemo in Resectable NSCLC
Neoadjuvant nivolumab (Opdivo) plus chemotherapy provided a statistically significant and clinically meaningful overall survival (OS) benefit vs chemotherapy alone in patients with resectable non–small cell lung cancer (NSCLC), according to findings from …